<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131595</url>
  </required_header>
  <id_info>
    <org_study_id>WEV-MVA-001</org_study_id>
    <nct_id>NCT04131595</nct_id>
  </id_info>
  <brief_title>Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects</brief_title>
  <official_title>Phase 1 Vaccination Trial to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JPM CBRN Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in&#xD;
      the 3 treatment groups receiving different doses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Actual">July 22, 2020</completion_date>
  <primary_completion_date type="Actual">July 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability: Number of subjects reporting any serious adverse events (SAE)</measure>
    <time_frame>within 7 months after vaccinations of subjects</time_frame>
    <description>Number of subjects reporting any serious adverse events (SAE)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Equine Encephalitis</condition>
  <arm_group>
    <arm_group_label>MVA-BN-WEV Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in treatment Group 1 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 107 Inf.U in 0.5 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVA-BN-WEV Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in treatment Group 2 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 108 Inf.U in 0.5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVA-BN-WEV Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in treatment Group 3 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 2 x 108 Inf.U in 2 x 0.5 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-WEV Dose 1</intervention_name>
    <description>1 x 10^7 Inf.U MVA-BN-WEV vaccine</description>
    <arm_group_label>MVA-BN-WEV Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-WEV Dose 2</intervention_name>
    <description>1 x 10^8 Inf.U MVA-BN-WEV vaccine</description>
    <arm_group_label>MVA-BN-WEV Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-WEV Dose 3</intervention_name>
    <description>2 x 10^8 Inf.U MVA-BN-WEV vaccine.</description>
    <arm_group_label>MVA-BN-WEV Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Male and female subjects ≥18 and ≤50 years of age at screening (SCR).&#xD;
&#xD;
          -  2. General good health, without clinically relevant medical illness, physical exam&#xD;
             findings, or laboratory abnormalities, as determined by the investigator.&#xD;
&#xD;
          -  3. Prior to performance of any trial specific procedures, the subject has read, signed&#xD;
             and dated an informed consent form (ICF), having been advised of the risks and&#xD;
             benefits of the trial in a language understood by the subject, and has signed the&#xD;
             Health Insurance Portability and Accountability Act authorization form (HIPAA).&#xD;
&#xD;
          -  4. Body mass index (BMI) ≥18.5 and ≤35.&#xD;
&#xD;
          -  5. Female subjects of childbearing potential and male subjects who are sexually active&#xD;
             with a female partner of childbearing potential must agree to the use of an effective&#xD;
             method of birth control from at least 30 days prior to administration of the vaccine&#xD;
             to until 30 days after the last vaccination. A woman is considered of childbearing&#xD;
             potential unless post-menopausal (defined as ≥12 months without a menstrual period at&#xD;
             SCR) or surgically sterilize (bilateral oophorectomy, bilateral tubal ligation,&#xD;
             hysterectomy). Acceptable contraception methods are restricted to abstinence&#xD;
             (abstinence only acceptable if refraining from heterosexual intercourse during the&#xD;
             entire period of 30 days prior to administration of the vaccine until 30 days after&#xD;
             the last vaccination), double barrier contraceptives, vasectomy, intrauterine&#xD;
             contraceptive devices or licensed hormonal products.&#xD;
&#xD;
          -  6. Women of Childbearing Potential (WOCBP) must have a negative serum pregnancy test&#xD;
             at SCR.&#xD;
&#xD;
          -  7. Negative human immunodeficiency virus antibody test (anti-HIV), negative hepatitis&#xD;
             B surface antigen (HBsAG) and negative antibody to hepatitis C virus.&#xD;
&#xD;
          -  8. Troponin I within normal limits at SCR.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Pregnant or breast-feeding women.&#xD;
&#xD;
          -  2. Subject has an acute or chronic medical condition that, in the opinion of the&#xD;
             investigator, would render the trial procedures unsafe or would interfere with the&#xD;
             evaluation of the responses, including but not limited to, neurologic, cardiovascular,&#xD;
             respiratory, hepatic, hematologic, rheumatologic, endocrine, gastrointestinal, renal,&#xD;
             autoimmune, or immunosuppressive conditions.&#xD;
&#xD;
          -  3. Laboratory parameters (such as complete blood count, serum biochemistry including&#xD;
             aspartate aminotransferase (AST), alanine amino transferase (ALT), alkaline&#xD;
             phosphokinase (AP), bilirubin, or creatinine values), pulse rate and/or blood&#xD;
             pressure, or electrocardiogram (ECG) outside normal range at SCR and deemed clinically&#xD;
             relevant by the investigator.&#xD;
&#xD;
          -  4. History of or active autoimmune disease; persons with vitiligo or thyroid disease&#xD;
             taking thyroid replacement are not excluded. History of Guillain-Barré syndrome or&#xD;
             Reye's syndrome.&#xD;
&#xD;
          -  5. Known or suspected impairment of immunologic functions including, but not limited&#xD;
             to, clinically significant liver disease, diabetes mellitus type I, moderate to severe&#xD;
             kidney impairment. A known immunodeficiency syndrome.&#xD;
&#xD;
          -  6. Known or suspected previous smallpox vaccination or vaccination with a&#xD;
             poxvirus-based vaccine.&#xD;
&#xD;
          -  7. Known or suspected previous alphavirus infections (Eastern Equine Encephalitis&#xD;
             Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), Western Equine Encephalitis&#xD;
             Virus (WEEV), Chikungunya).&#xD;
&#xD;
          -  8. History of malignancy other than squamous cell or basal cell skin cancer, unless&#xD;
             there has been surgical excision at least 6 months prior to SCR that is considered to&#xD;
             have achieved cure. Subjects with history of skin cancer must not be vaccinated at the&#xD;
             previous tumor site.&#xD;
&#xD;
          -  9. Clinically significant mental disorder not adequately controlled by medical&#xD;
             treatment.&#xD;
&#xD;
          -  10. Active or recent history of chronic alcohol abuse and/or intravenous and/or nasal&#xD;
             drug abuse (within the time period of 6 months before SCR).&#xD;
&#xD;
          -  11. History of allergic disease or reactions likely to be exacerbated by any component&#xD;
             of the vaccine, e.g. tris(hydroxymethyl)-amino methane, chicken embryo fibroblast&#xD;
             proteins, gentamicin, ciprofloxacin.&#xD;
&#xD;
          -  12. Known allergy to eggs.&#xD;
&#xD;
          -  13. History of anaphylaxis or severe allergic reaction to any vaccine.&#xD;
&#xD;
          -  14. Having received any vaccinations or planned vaccinations with a live vaccine&#xD;
             within 30 days prior to first or after last trial vaccination.&#xD;
&#xD;
          -  15. Having received any vaccinations or planned vaccinations with an inactivated&#xD;
             vaccine within 14 days prior to first or after last trial vaccination.&#xD;
&#xD;
          -  16. Recent blood donation (including platelets, plasma and red blood cells) within 4&#xD;
             weeks prior screening, or planned blood donations during active trial phase (until EAP&#xD;
             Visit).&#xD;
&#xD;
          -  17. Chronic systemic administration (defined as more than 14 days) of &gt;5 mg prednisone&#xD;
             (or equivalent)/day or any other immunemodifying drugs during a period starting 3&#xD;
             months prior to administration of the vaccine and ending at the last visit of the&#xD;
             active treatment phase. The use of topical, inhaled, ophthalmic and nasal&#xD;
             glucocorticoids is allowed.&#xD;
&#xD;
          -  18. Post organ transplant subjects whether or not receiving chronic immunosuppressive&#xD;
             therapy.&#xD;
&#xD;
          -  19. Administration or planned administration of immunoglobulins and/or any blood&#xD;
             products during a period starting 3 months prior to administration of the vaccine and&#xD;
             ending at the last visit of the active treatment phase. Receipt of packed red blood&#xD;
             cells given for an emergent indication in an otherwise healthy person, and not&#xD;
             required as ongoing treatment is not exclusionary (for example packed red blood cells&#xD;
             emergently given during an elective surgery).&#xD;
&#xD;
          -  20. History of coronary heart disease, myocardial infarction, angina, congestive heart&#xD;
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood&#xD;
             pressure, significant arrhythmia with or without corrective/ablative surgery, or any&#xD;
             other heart condition under the care of a doctor.&#xD;
&#xD;
          -  21. Use of any investigational or non-registered drug or vaccine other than the trial&#xD;
             vaccine within 30 days preceding the first dose of the trial vaccine, or planned&#xD;
             administration of such a drug during the trial period until the Follow-Up (FU) Visit 6&#xD;
             months after the last vaccination visit.&#xD;
&#xD;
          -  22. Clinical trial site personnel involved in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Fierro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JCCT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalomyelitis, Equine</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

